Limits...
Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema.

Hartman JE, Klooster K, Gortzak K, ten Hacken NH, Slebos DJ - Respirology (2014)

Bottom Line: At 1-year follow-up, all clinical outcomes significantly improved compared with baseline.Follow-up of the patients treated with LVR-coils in our pilot studies showed that the coil treatment is safe with no late pneumothoraces, coil migrations or unexpected adverse events.Clinical benefit gradually declines over time; at 3 years post-treatment, around 50% of the patients maintained improvement in 6MWD, SGRQ and mMRC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

No MeSH data available.


Related in: MedlinePlus

Decline in forced expiratory volume in 1 s (FEV1) before and after the LVR-coil treatment. Baseline and post-treatment FEV1 shown as mean (±standard deviation). ‘’: before treatment; ‘’: trend line; ‘’: during study participation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4321042&req=5

fig03: Decline in forced expiratory volume in 1 s (FEV1) before and after the LVR-coil treatment. Baseline and post-treatment FEV1 shown as mean (±standard deviation). ‘’: before treatment; ‘’: trend line; ‘’: during study participation.

Mentions: At least three previously performed FEV1 measurements were available for 30/38 patients (79%). The median number of available measurements was 9 (range 3–23) and the median number of days for the first available measurement before treatment was 1989 days (range: 292–4376). The mean decline in FEV1 before the LVR-coil treatment was −0.082 L/year (standard deviation: 0.073). This was significantly different compared with the mean decline in FEV1 during study participation (mean decline: −0.036 L/year, P = 0.018). The decline in FEV1 after more than 6 months of follow-up did not significantly differ compared with the decline before the treatment (mean decline: −0.060 L/year, P = 0.45) (Fig. 3).


Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema.

Hartman JE, Klooster K, Gortzak K, ten Hacken NH, Slebos DJ - Respirology (2014)

Decline in forced expiratory volume in 1 s (FEV1) before and after the LVR-coil treatment. Baseline and post-treatment FEV1 shown as mean (±standard deviation). ‘’: before treatment; ‘’: trend line; ‘’: during study participation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4321042&req=5

fig03: Decline in forced expiratory volume in 1 s (FEV1) before and after the LVR-coil treatment. Baseline and post-treatment FEV1 shown as mean (±standard deviation). ‘’: before treatment; ‘’: trend line; ‘’: during study participation.
Mentions: At least three previously performed FEV1 measurements were available for 30/38 patients (79%). The median number of available measurements was 9 (range 3–23) and the median number of days for the first available measurement before treatment was 1989 days (range: 292–4376). The mean decline in FEV1 before the LVR-coil treatment was −0.082 L/year (standard deviation: 0.073). This was significantly different compared with the mean decline in FEV1 during study participation (mean decline: −0.036 L/year, P = 0.018). The decline in FEV1 after more than 6 months of follow-up did not significantly differ compared with the decline before the treatment (mean decline: −0.060 L/year, P = 0.45) (Fig. 3).

Bottom Line: At 1-year follow-up, all clinical outcomes significantly improved compared with baseline.Follow-up of the patients treated with LVR-coils in our pilot studies showed that the coil treatment is safe with no late pneumothoraces, coil migrations or unexpected adverse events.Clinical benefit gradually declines over time; at 3 years post-treatment, around 50% of the patients maintained improvement in 6MWD, SGRQ and mMRC.

View Article: PubMed Central - PubMed

Affiliation: Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Groningen Research Institute for Asthma and COPD, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

No MeSH data available.


Related in: MedlinePlus